Following Novo Nordisk, Eli Lilly Lands Partner for R&D of Longer-Acting Metabolic Meds

Following Novo Nordisk, Eli Lilly Lands Partner for R&D of Longer-Acting Metabolic Meds

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology to its metabolic medicines; the deal follows a similar move Novo Nordisk starting an alliance with Ascendis. The post Following Novo Nordisk, Eli Lilly Lands Partner for R&D of Longer-Acting Metabolic Meds appeared first on MedCity News.

Lilly partners with Camurus in search of a long-lasting obesity drug

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help extend the durability of up to four of its weight-loss medicines.

Camurus and Eli Lilly collaborate on long-acting incretin products

Lilly will get exclusive, global rights to research, develop, manufacture and commercialise these therapies with Camurus’ FluidCrystal technology. The agreement includes up to four drug compounds from Lilly. The post Camurus and Eli Lilly collaborate on long-acting incretin products appeared first on Pharmaceutical Business review.

Lilly makes a move for long-acting incretins in tech deal with Swedish biotech

Eli Lilly has tapped Camurus in a deal worth up to $870 million for its drug delivery technology to develop four long-acting incretin candidates. The technology can be used on any of Lilly’s dual GLP ...